BUSINESS SEGMENT INFORMATION (Tables)

6 Months Ended

Jun. 30, 2012

Segment Reporting [Abstract]

Net sales of key products [Text Block]

		Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions		2012		2011		2012		2011
Plavix* (clopidogrel bisulfate)		$	741	$	1,865	$	2,434	$	3,627
Avapro*/Avalide* (irbesartan/irbesartan-hydrochlorothiazide)			117		251		324		541
Eliquis (apixaban)			1		-		1		-
Abilify* (aripiprazole)			711		706		1,332		1,330
Reyataz (atazanavir sulfate)			406		396		764		762
Sustiva (efavirenz) Franchise			388		371		774		714
Baraclude (entecavir)			357		292		682		567
Erbitux* (cetuximab)			179		173		358		338
Sprycel (dasatinib)			244		193		475		365
Yervoy (ipilimumab)			162		95		316		95
Orencia (abatacept)			290		228		544		427
Nulojix (belatacept)			3		2		4		2
Onglyza/Kombiglyze (saxagliptin/saxagliptin and metformin)			172		112		333		193
Mature Products and All Other			672		750		1,353		1,484
	Net Sales	$	4,443	$	5,434	$	9,694	$	10,445